Hemophilia B Without Inhibitor
4
0
1
1
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Treatment Research
5 treatments under study, led by Middle Dose Kl001
Related Conditions
Often studied with 5 related conditions
Clinical Risk Assessment
Based on trial outcomes
Low Risk
Score: 15/100
0.0%
0 terminated out of 4 trials
100.0%
+13.4% vs benchmark
25%
1 trials in Phase 3/4
100%
1 of 1 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.6%
Based on 1 completed trials
Clinical Trials (4)
Efficacy and Safety of KN057 Prophylaxis in Patients With Haemophilia A or B Without Inhibitors
Safety and Efficacy Clinical Study of Severe Hemophilia B Treatment With KL001
Safety and Efficacy Clinical Study of Severe Hemophilia B Treatment With KL001
Study of Coagulation Faction VIIa Variant Marzeptacog Alfa (Activated) in Adult Subjects With Hemophilia
Research Network
Common Treatments
- Middle Dose Kl0012
- High Dose Kl0012
- Low Dose Kl0012
- Marzaa Marzeptacog Alfa Activated1
- Kn0571
Active Sponsors
- Affiliated Hospital of Guangdong Medical University1
- Catalyst Biosciences1
- Zhejiang University1
- Suzhou Alphamab Co., Ltd.1
Top Investigators
Henan Cancer Hospital
The Second Affiliated Hospital of Chongqing Medical University
The First Affiliated Hospital of China University of Science and Technology (Anhui Provincial)
Huai'an Second People'Hospital
The first affiliated hospital of jiangxi medical college
Related Conditions
- Hemophilia A Without Inhibitor2
- Hemophilia A1
- Hemophilia B With Inhibitor1
- Hemophilia B1
- Hemophilia A With Inhibitor1